| 1. |
- Kim, Joon Tae, et al.
(författare)
-
Dual antiplatelet Use for extended period taRgeted to AcuTe ischemic stroke with presumed atherosclerotic OrigiN (DURATION) trial : Rationale and design
- 2023
-
Ingår i: International Journal of Stroke. - : SAGE Publications. - 1747-4930 .- 1747-4949. ; 18:8, s. 1015-1020
-
Tidskriftsartikel (refereegranskat)abstract
- Rationale: The optimal duration of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin for the large artery atherosclerotic (LAA) stroke subtype has been debated. Aims: To determine whether the 1-year risk of recurrent vascular events could be reduced by a longer duration of DAPT in patients with the LAA stroke subtype. Methods and study design: A total of 4806 participants will be recruited to detect a statistically significant relative risk reduction of 22% with 80% power and a two-sided alpha error of 0.05, including a 10% loss to follow-up. This is a registry-based, multicenter, prospective, randomized, open-label, blinded end point study designed to evaluate the efficacy and safety of a 12-month duration of DAPT compared with a 3-month duration of DAPT in the LAA stroke subtype. Patients will be randomized (1:1) to either DAPT for 12 months or DAPT for 3 months, followed by monotherapy (either aspirin or clopidogrel) for the remaining 9 months. Study outcomes: The primary efficacy outcome of the study is a composite of stroke (ischemic or hemorrhagic), myocardial infarction, and all-cause mortality for 1 year after the index stroke. The secondary efficacy outcomes are (1) stroke, (2) ischemic stroke or transient ischemic attack, (3) hemorrhagic stroke, and (4) all-cause mortality. The primary safety outcome is major bleeding. Discussion: This study will help stroke physicians determine the appropriate duration of dual therapy with clopidogrel-aspirin for patients with the LAA stroke subtype. Trial registration: URL: https://cris.nih.go.kr/cris. CRIS Registration Number: KCT0004407.
|
|
| 2. |
- Lee, Da Hye, et al.
(författare)
-
Phase formation behavior and hydrogen sorption characteristics of TiFe0.8Mn0.2 powders prepared by gas atomization
- 2023
-
Ingår i: International journal of hydrogen energy. - : Elsevier BV. - 0360-3199 .- 1879-3487. ; 48:71, s. 27697-27709
-
Tidskriftsartikel (refereegranskat)abstract
- In this article we have investigated the phase formation behavior and hydrogen storage characteristics of TiFe0.8Mn0.2 samples produced by electrode induction melting gas at-omization (EIGA) as well as conventional vacuum arc-melting (VAM). TiFe (46Ti-46Fe-8Mn (wt%) with cubic, CsCl-type structure) and C14 Laves (37Ti-51Fe-12Mn (wt%) with hex-agonal, MgZn2-type structure) phases were detected in both atomized powders and crushed ingots, the latter possessing a lower fraction of Laves phase. Microstructural characterization included electron probe micro-analysis (EPMA) and transmission electron microscopy (TEM), which evidenced the existence of a non-equilibrium Ti2Fe phase in the atomized powders. The formation of this additional secondary phase was attributed to the rapid cooling rate during powder manufacturing, based on earlier findings and phase formation thermodynamic calculations combined with Scheil solidification simulations. In addition, kinetics and pressure-composition isotherms (PCIs) were acquired to determine both absorption and desorption enthalpy/entropy, as well as to study the influence of the synthesis route (and hence the resulting microstructure) on kinetics, thermodynamics and reaction mechanisms of the TiFe0.8Mn0.2 alloy. & COPY; 2023 Hydrogen Energy Publications LLC. Published by Elsevier Ltd. All rights reserved.
|
|
